Phages and phage-borne enzymes as new antibacterial agents

McCallin, Shawna; Drulis-Kawa, Zuzanna; Ferry, Tristan; Pirnay, Jean-Paul; Nir-Paz, Ran

doi:10.1016/j.cmi.2023.10.018

Cited by 3 publications

(1 citation statement)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the early stages of phage therapy in western medicine and the yet absence of authorized treatments makes it even more challenging. 3 , 4 , 5 Pipelines for phage therapy are available in some places. 6 , 7 Nevertheless, due to the predominant personalized, compassionate basis, a standardized protocols for phage susceptibility testing and treatment are lacking.…”

Section: Before You Beginmentioning

confidence: 99%

Protocol for phage matching, treatment, and monitoring for compassionate bacteriophage use in non-resolving infections

Onallah,

Yerushalmy,

Braunstein

et al. 2024

STAR Protocols

Self Cite

View full text Add to dashboard Cite

Section: Before You Beginmentioning

confidence: 99%

Protocol for phage matching, treatment, and monitoring for compassionate bacteriophage use in non-resolving infections

Onallah,

Yerushalmy,

Braunstein

et al. 2024

STAR Protocols

Self Cite

View full text Add to dashboard Cite

Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic programme

Ferry,

Bouar,

Briot

et al. 2024

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps

Gigante,

Alm,

Melchiorri

et al. 2024

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Antimicrobial resistance (AMR) is a major global health threat estimated to have caused the deaths of 1.27 million people in 2019, which is more than HIV/AIDS and malaria deaths combined. AMR also has significant consequences on the global economy. If not properly addressed, AMR could immensely impact the world’s economy, further increasing the poverty burden in low- and middle-income countries. To mitigate the risk of a post-antibiotic society, where the ability to effectively treat common bacterial infections is being severely threatened, it is necessary to establish a continuous supply of new and novel antibacterial medicines. However, there are gaps in the current pipeline that will prove difficult to address, given the time required to develop new agents. To understand the status of upstream antibiotic development and the challenges faced by drug developers in the early development stage, the World Health Organization has regularly assessed the preclinical and clinical antibacterial development pipeline. The review identifies potential new classes of antibiotics or novel mechanisms of action that can better address resistant bacterial strains. This proactive approach is necessary to stay ahead of evolving resistance patterns and to support the availability of effective treatment options. This review examines the trends in preclinical development and attempts to identify gaps and potential opportunities to overcome the numerous hurdles in the early stages of the antibacterial research and development space.

show abstract

Phages and phage-borne enzymes as new antibacterial agents

Cited by 3 publications

References 68 publications

Protocol for phage matching, treatment, and monitoring for compassionate bacteriophage use in non-resolving infections

Protocol for phage matching, treatment, and monitoring for compassionate bacteriophage use in non-resolving infections

Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic programme

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps

Contact Info

Product

Resources

About